Screener
Recursion Pharmaceuticals, Inc. RXRX Contract Liabilities
Contract Liabilities at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Operating lease liabilities | 13,249 | 12,663 |
| Notes payable and financing lease liabilities | 9,443 | 9,091 |
| Total current liabilities | 119,886 | 147,707 |
| Unearned revenue, non-current | 112,818 | 114,012 |
| Operating lease liabilities, non-current | 39,193 | 46,647 |
| Notes payable and financing lease liabilities, non-current | 4,753 | 9,564 |
| Deferred tax liabilities | 18,313 | 23,255 |
| Other liabilities, non-current | 2,702 | 2,080 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s contract liabilities?
- Recursion Pharmaceuticals, Inc. (RXRX) reported contract liabilities of $112.82M in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s contract liabilities changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s contract liabilities decreased by 10.6% year-over-year, from $126.24M to $112.82M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s contract liabilities?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s contract liabilities has grown at a 46.9% compound annual growth rate (CAGR), from $16.67M to $114.01M.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.
Ask your AI about Recursion Pharmaceuticals, Inc.'s contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude